tert-butyl 2-(8-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-yl)acetate | 1262008-54-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: tert-butyl 2-(8-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-yl)acetate
• 英文别名: tert-butyl 2-[8-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-yl]acetate
• CAS: 1262008-54-7
• 化学式: C₃₀H₃₄F₃NO₄
• 分子量: 529.599
• InChiKey: COZMZZRIBRFEEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  49.7
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tert-butyl 2-(8-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-yl)acetate 在 L-半胱氨酸 、 三氟乙酸 作用下， 生成 2-(8-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-yl)acetic acid
  参考文献：
  名称：

  Design and synthesis of new tricyclic indoles as potent modulators of the S1P1 receptor

  摘要：

  Modulators of S1P(1) have proven utility for the treatment of autoimmune disease and efforts to identify new agents with improved safety and pharmacokinetic parameters are ongoing. Several new S1P(1) chemotypes were designed and optimized for potency and oral bioavailability. These new agents are characterized by a 'tricyclic fused indole array' and are highly potent agonists of the S1P(1) receptor. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.11.089
• 作为产物：
  描述：

  5-benzyloxy-1H-indole-2-carbaldehyde 在 10 wt% Pd(OH)2 on carbon 、 四丁基氟化铵 、 甲酸铵 、 sodium hydride 、 potassium carbonate 、 cesium fluoride 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 tert-butyl 2-(8-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-yl)acetate
  参考文献：
  名称：

  Design and synthesis of new tricyclic indoles as potent modulators of the S1P1 receptor

  摘要：

  Modulators of S1P(1) have proven utility for the treatment of autoimmune disease and efforts to identify new agents with improved safety and pharmacokinetic parameters are ongoing. Several new S1P(1) chemotypes were designed and optimized for potency and oral bioavailability. These new agents are characterized by a 'tricyclic fused indole array' and are highly potent agonists of the S1P(1) receptor. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.11.089

文献信息

• [EN] MODULATORS OF THE SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DU RÉCEPTEUR SPHINGOSINE-1-PHOSPHATE (S1P) UTILES POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À CEUX-CI
  申请人：ARENA PHARM INC

  公开号：WO2011005295A8

  公开（公告）日：2012-09-20